Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 501 to 525 of 2047

TitleReference numberPublishedLast updated
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Endoluminal gastroplication for gastro-oesophageal reflux diseaseHTG661
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionHTG662
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Transvenous obliteration for gastric varicesHTG658
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Maribavir for treating refractory cytomegalovirus infection after transplantTA860
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Trabeculectomy with a biodegradable collagen matrix implant for glaucomaHTG656
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213

Results per page

  1. 10
  2. 25
  3. 50
  4. All